Quris Technologies

Executive Summary

Quris Technologies is an Israeli-American biotech startup that addresses the drug industry's 89% clinical trial failure rate by integrating organ-on-a-chip technology with machine learning. Its Bio-AI Clinical Prediction Platform generates proprietary, genomically diverse patient-on-a-chip data to train classification models that predict human drug safety and efficacy more accurately than traditional animal models. This approach enables faster, animal-free preclinical validation, targeting pharma partners seeking to reduce costly late-stage failures. Founded in 2020 and based in Tel Aviv, the company has raised $28 million to advance its platform, which combines high-throughput microfluidic chips with artificial intelligence to simulate human organ responses. By replacing animal testing with human-relevant data, Quris aims to de-risk drug development and accelerate the time-to-market for new therapies. The company's technology has attracted interest from top pharmaceutical firms, positioning it as a leader in the emerging field of AI-driven drug testing. Looking ahead, Quris is poised to achieve significant milestones, including securing its first major pharma partnership, closing a Series B financing round, and publishing key preclinical validation data. These catalysts will validate its platform and drive commercialization. With a strong scientific foundation and a clear value proposition, Quris Technologies offers a compelling solution to a persistent industry pain point, backed by a capable team and growing investor confidence. The company's ability to deliver on its milestones will be critical to its long-term success and market adoption.

Upcoming Catalysts (preview)

• Q3 2026First Major Pharma Collaboration40% success
• Q4 2026Series B Financing50% success
• Q3 2026Publication of Preclinical Validation Data70% success